Sotyktu

News

The FDA has started a review of the marketing application for Takeda's TYK2 inhibitor zasocitinib in psoriasis, setting up a decision in mid-March.

News

New data with Takeda's TYK2 inhibitor zasocitinib suggest it is significantly more effective than BMS's Sotyktu in the treatment of psoriasis.

News

Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.

News

Takeda intends to file for approval of its oral psoriasis therapy zasocitinib next year, with Bristol Myers Squibb's Sotyktu in its sights.

News

Bristol Myers Squibb expands its DTC sales in the US with the addition of psoriasis drug Sotyktu at an 80% discount for cash buyers.

News

J&J wants to turn the screw in the psoriasis market with a new head-to-head trial pitting oral IL-23 drug icotrokinra against Stelara.